Page 1

DiaSorin PRESS RELEASE The Diagnostic Specialist REVENUES AND PROFITABILITY CONTINUE UPWARD MOMENTUM IN THE FIRST HALF OF 2021 , WITH GUIDANCE RAISED FOLLOWING THE ACQUISITION OF LUMINEX H1 2021 RESULTS REVENUES : € 515.4 million , + 34.8 % ( + 39.6 % at CER ) compared to H1'20 . It should be noted that ex - COVID revenues in H1'21 grew by 21.4 % at CER compared to H1'20 . Sales of SARS - CoV - 2 serology and molecular diagnostic tests were € 177.3 million ( € 94.6 million in H1'20 ; + 87.4 % ) . Lastly , in Q2'21 ex - COVID business was + 52.5 % at CER compared to Q2'20 , while total revenues grew by 23.0 % at CER . ADJUSTED EBITDA¹ : € 244.2 million , + 58.9 % ( + 64.0 % at CER ) , equal to 47.4 % of Group revenues ( 47.2 % at CER ) . The result reflects the sales growth in H1'21 , the operating leverage generated by high volumes of tests for SARS - CoV - 2 and the containment of operating expenses . EBITDA was € 231.3 million , + 50.6 % ( + 55.6 % at CER ) compared to H1'20 , equal to 44.9 % of Group revenues ( 40.2 % in H1’20 ) . EBIT : € 201.9 million , + 63.3 % , equal to 39.2 % of Group revenues ( 32.3 % in H1'20 ) . NET PROFIT : € 150.0 million , + 58.4 % , equal to 29.1 % of Group revenues ( 24.8 % in H1'20 ) . NET FINANCIAL POSITION : + € 436.3 million at June 30 , 2021 ( + € 305.3 million at 31 December 2020 ) . The increase , equal to € 131.0 million , includes the dividend distribution amounting to € 54.0 million , as resolved by the Shareholders ' Meeting on April 22 , 2021 . FREE CASH FLOW : € 125.8 million in H1'21 ( € 73.9 million in H1'20 ) . IMMUNODIAGNOSTIC ANALYZERS INSTALLED : 9,029 units at June 30 , 2021. Strong performance of LIAISON® XL placements in H1'21 ( +299 units ) for a total installed base of around 5,400 units . NEW FY 2021 GUIDANCE AT CONSTANT EXCHANGE RATES : following the recent acquisition of Luminex , completed on July 14 , 2021 , DiaSorin provides the following new FY 2021 guidance : ' REVENUES : growth between 35 % and 40 % , equal to approx . € 1.2 billion ADJUSTED EBITDA¹ MARGIN : equal to approx . 42 % The expected revenues growth at CER and on a like - for - like basis is between 15 % and 20 % , of which ex - COVID revenues around + 15 % . The COVID - 19 pandemic continues to impact both the global economy and , even more deeply , the sector in which DiaSorin operates , leading to uncertainty in anticipating future purchasing behavior trends in laboratories and hospitals . The guidance range for revenues reflects the difficulty in accurately forecasting sales performance of COVID tests due to the unpredictability of viral mutations that may affect vaccine's efficacy and the speed and pervasiveness of vaccine rollout in the different geographies where DiaSorin operates . The guidance reflects DiaSorin's current visibility into market conditions , customer order patterns for Group products and is based on the current assumptions about the effects of the virus spread . IMPACT OF THE COVID - 19 PANDEMIC ON BUSINESS : H1'21 was marked by the ongoing COVID - 19 pandemic , without any negative impact on the diagnostic sector . In this context , DiaSorin has not identified any COVID - 19 - associated risk that may threaten its business continuity and no disruptions in all Group sites have been experienced in research , manufacturing and distribution activities , carried out in compliance with the provisions intended to ensure its employees ' safety . DIASORIN INVESTOR DAY 2021 The Company's Industrial Plan , expected to be approved by the end of September 2021 , has been postponed to provide the financial community with a more detailed representation of the strategies of growth deriving from the integration of Luminex in the Group's business perimeter . The new Industrial Plan will therefore be presented the Board of Directors and subsequently to the financial community by mid - December 2021. More information will be made available in the “ Investors ” section at www.diasoringroup.com . ¹Adjusted EBITDA = EBITDA net of " one - off " costs related to the acquisition of Luminex ( € 12.9 million in the first 6 months of 2021 ) 1